Financials in USD. Standardized financial statements.
A compact view of how CAMP4 Therapeutics Corporation turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.50M | $652,000 | $350,000 | $0 | $295.84M | $308.59M | $366.11M | $363.80M | $365.91M | $351.10M |
| Revenue Growth? | +436.5% | +86.3% | 0.0% | -100.0% | -4.1% | -15.7% | +0.6% | -0.6% | +4.2% | 0.0% |
| Cost of Revenue? | $1.64M | $0 | $0 | $0 | $173.95M | $186.18M | $222.80M | $216.04M | $215.02M | $207.75M |
| Gross Profit? | $1.86M | $652,000 | $350,000 | $0 | $121.89M | $122.41M | $143.30M | $147.76M | $150.89M | $143.35M |
| Gross Margin? | +53.1% | +100.0% | +100.0% | 0.0% | +41.2% | +39.7% | +39.1% | +40.6% | +41.2% | +40.8% |
| Operating Expenses? | $53.92M | $53.74M | $52.23M | $45.00M | $134.76M | $125.87M | $159.96M | $120.05M | $142.94M | $142.01M |
| Operating Income? | -$52.06M | -$53.09M | -$51.88M | -$45.00M | -$15.31M | -$3.87M | -$16.77M | $19.70M | $7.96M | $1.34M |
| EBITDA? | -$50.42M | -$51.39M | -$50.20M | -$44.12M | $7.49M | $18.13M | $15.22M | $47.05M | $31.36M | $24.71M |
| Income Before Tax | -$80.40M | -$51.79M | -$49.29M | -$44.19M | -$30.06M | -$20.60M | -$58.32M | $23.86M | $28.71M | -$6.96M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $1.09M | $561,000 | $20.45M | -$1.33M | $10.68M | -$1.10M |
| Net Income? | -$80.40M | -$51.79M | -$49.29M | -$44.19M | -$31.15M | -$21.16M | -$78.77M | $18.40M | $16.62M | -$7.15M |
| EPS? | $-2.65 | $-2.66 | $-4.07 | $-0.90 | $-0.88 | $-0.62 | $-2.35 | $0.53 | $0.47 | $-0.20 |
| Diluted EPS? | $-2.65 | $-2.66 | $-4.07 | $-0.90 | $-0.88 | $-0.62 | $-2.34 | $0.52 | $0.46 | $-0.20 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality